53266-94-7

Usage

Uses

Used in Pharmaceutical Synthesis:
Ethyl 2-amino-4-thiazoleacetate is used as a building block for the synthesis of various pharmaceutical compounds, particularly for creating biologically active molecules with potential applications in the medical field.
Used in Antibiotic Production:
Ethyl 2-amino-4-thiazoleacetate is also utilized in the synthesis of antibiotics, such as Cefdinir (C242675) derivatives, contributing to the development of new and effective treatments for bacterial infections.
Used in Coordination Chemistry:
Due to its strong coordination ability and diverse coordination modes, Ethyl 2-amino-4-thiazoleacetate is used as a ligand in coordination chemistry, allowing for the formation of various complexes with potential applications in different industries.

InChI:InChI=1/C7H10N2O2S/c1-2-11-6(10)3-5-4-12-7(8)9-5/h4H,2-3H2,1H3,(H2,8,9)

Upstream product

• 29676-71-9 2-amino-4-thiazoleacetic acid 
• 64-17-5 ethanol 
• 638-07-3 ethyl (2-chloroaceto)acetate 
• 17356-08-0 thiourea 
• 141-97-9 ethyl acetoacetate 
• 420-04-2 CYANAMID 
• 13176-46-0 4-bromoethyl acetoacetate 
• 84911-18-2 ethyl 2-bromoacetoacetate 

Downstream Products

• 57626-46-7 3-ethoxycarbonylmethyl-6-phenylimidazo<2,1-b>thiazole 
• 68347-85-3 ethyl 6-(4'-chlorophenyl)imidazo<2,1-b>thiazole-3-acetate 
• 294886-87-6 [2-(2-chloro-2-phenyl-acetylamino)-thiazol-4-yl]-acetic acid ethyl ester 
• 19749-93-0 2-chloroacetamido-4-thiazolyl acetic acid ethyl ester 
• 375844-31-8 ethyl 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-1,3-thiazol-4-yl)acetate 
• 745055-14-5 {2-[(imidazole-1-carbothioyl)-amino]-thiazol-4-yl}-acetic acid ethyl ester 
• 329699-54-9 2-[[(4-chlorophenyl)carbonyl]amino]-1,3-thiazol-4-yl-acetic acid ethyl ester 
• 92592-05-7 2-(4-nitrobenzyloxycarbonylamino)thiazol-4-ylacetic acid 
• 92592-03-5 ethyl 2-(4-nitrobenzyloxycarbonylamino)thiazol-4-ylacetate 
• 121953-08-0 4-ethoxycarbonylmethyl-2-imino-3-phenacyl-2,3-dihydrothiazole 
• 121953-26-2 4-ethoxycarbomylmethyl-3-phenacyl-2-(2-thenoylimino)-2,3-dihydrothiazole 
• 121953-15-9 4-ethoxycarbonylmethyl-3-phenacyl-2-trifluoroacetylimino-2,3-dihydrothiazole 

Relevant academic research and scientific papers

Synthesis of 2-Aminothiazole Derivatives in Easy Two-Step, One-Pot Reaction

Condensation of brominated ethyl acetoacetate with thiourea gives 2-amino-5-ethoxycarbonyl-4-methylthiazole (1) and ethyl α-(2-amino-4-thiazolyl)acetate (2), indicating that bromination of the substrate occurs on both sides of the carbonyl group. X-ray di

A Novel Minor Groove Binder as a Potential Therapeutic Agent for Myotonic Dystrophy Type 1

Myotonic dystrophy type 1 (DM1) is a multisystemic neuromuscular disorder that is inherited in an autosomal dominant manner. DM1 originates in a (CTG?CAG) repeat expansion in the 3’-UTR of the dystrophia myotonic protein kinase (DMPK) gene on chromosome 19. One of the transcripts, r(CUG)exp, is toxic in various ways. Herein we report a rationally designed small molecule with a thiazole peptidomimetic unit that can serve as a minor groove binder for the nucleic acid targets. This peptide unit linked to two triaminotriazine recognition units selectively binds to d(CTG)exp to inhibit the transcription process, and also targets r(CUG)exp selectively to improve representative DM1 pathological molecular features, including foci formation and pre-mRNA splicing defects in DM1 model cells. As such, it represents a new structure type that might serve as a lead compound for future structure-activity optimization.

One-pot method for preparing cefotiam intermediate 2-aminothiazole-4-acetic acid

The invention discloses a one-pot method for preparing a cefotiam intermediate that is 2-aminothiazole-4-acetic acid. The method is technically characterized by comprising the following steps: 1) by taking water as a solvent, carrying out ring closing by using thiourea and ethyl 4-chloroacetoacetate at a proper temperature and a proper molar ratio to generate ethyl 2-aminothiazole-4-acetate; afterthe reaction is finished, directly carrying out the next step of reaction on the reaction solution; 2) adding a certain amount of an alkali into the reaction solution for a hydrolysis reaction at a proper temperature, and 3) after the reaction is finished, adding a certain amount of an acid into the reaction solution at a proper temperature to adjust the pH value, and separating out the product.

Target-Directed Azide-Alkyne Cycloaddition for Assembling HIV-1 TAR RNA Binding Ligands

The highly conserved HIV-1 transactivation response element (TAR) binds to the trans-activator protein Tat and facilitates viral replication in its latent state. The inhibition of Tat–TAR interactions by selectively targeting TAR RNA has been used as a strategy to develop potent antiviral agents. Therefore, HIV-1 TAR RNA represents a paradigmatic system for therapeutic intervention. Herein, we have employed biotin-tagged TAR RNA to assemble its own ligands from a pool of reactive azide and alkyne building blocks. To identify the binding sites and selectivity of the ligands, the in situ cycloaddition has been further performed using control nucleotide (TAR DNA and TAR RNA without bulge) templates. The hit triazole-linked thiazole peptidomimetic products have been isolated from the biotin-tagged target templates using streptavidin beads. The major triazole lead generated by the TAR RNA presumably binds in the bulge region, shows specificity for TAR RNA over TAR DNA, and inhibits Tat–TAR interactions.

Study on a New Method for Synthesis of Mirabegron

Mirabegron is a muscle relaxing drug for the treatment of overactive bladder. The existing synthetic methods for mirabegron produced intermediate product 4-(2-(phenethylamino)ethyl)aniline, which complicated the final product purification process. In this study, we designed a new synthetic route for mirabegron with low cost starting materials and a production of mirabegron at a 99.6% purity and a 61% overall yield. Particularly, this new synthetic route did not produce side product 4-(2-(phenethylamino)ethyl)aniline, which significantly simplified the product purification process.

Preparation method and application of 2-(4-oxo-thiazoline-2-imino)thiazole-4-acetic acid derivative

The invention discloses a 2-(4-oxo-thiazoline-2-imino)thiazole-4-acetic acid derivative as shown in the structural formulas I and II, a pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition comprising the derivative and the pharmaceutically acceptable salt of the derivative, as well as application of the derivative to preparation of an influenza virus neuraminidase inhibitor.

Synthesizing method of {2-[2-(2-amino-4-thiazolyl)-amino acetyl]-4-thiazolyl}-acetic acid

The invention discloses a synthesizing method of {2-[2-(2-amino-4-thiazolyl)-amino acetyl]-4-thiazolyl}-acetic acid, belongs to the technical field of medicine synthesis, and provides a new synthesizing method of {2-[2-(2-amino-4-thiazolyl)-amino acetyl]-4-thiazolyl}-acetic acid. The synthesizing method comprises the following synthesizing steps of (1) esterification reaction: reacting (2-Aminothiazole-4-yl)acetic acid and ethanol into ester, so as to obtain an intermediate product A; (2) amino protection: reacting (2-Aminothiazole-4-yl)acetic acid and t-butyloxycarboryl, so as to generate an intermediate product B; (3) amide condensation reaction: condensing the intermediate product A and the intermediate product B by a condensing agent, so as to generate an intermediate product C; (4) deprotection reaction: removing ester and t-butyloxycarboryl from the intermediate product C by trifluoroacetic acid, so as to obtain a target product. The synthesizing method has the advantages that the cost is low, the yield rate of the product is high, and the synthesizing method is suitable for large-scale industrial production.

COSMETIC USES AND METHODS FOR INDOLINE GRANZYME B INHIBITOR COMPOSITIONS

Cosmetic uses and methods for indoline granzyme B inhibitor compounds in compositions with a cosmetically acceptable carrier. Uses and methods for treating, reducing or inhibiting the appearance of ageing in the skin are provided. Also provided are compositions and formulation for cosmetic uses and methods of maintaining a youthful appearance, reducing an appearance of ageing, inhibiting an appearance of ageing, reducing a rate of an appearance of ageing, reducing a skin inelasticity, reducing a rate of increasing skin inelasticity, maintaining a skin elasticity, and increasing the density of hair follicles of a skin of a subjecl. The uses and methods comprise applying/administering an indoline granzyme B inhibitor to a skin, or a portion of a skin of the subject.

Chromophore-linked substrate (CLS405): Probing metallo-β-lactamase activity and inhibition

Serine- and metallo-β-lactamases present a threat to the clinical use of nearly all β-lactam antibiotics, including penicillins, cephalosporins, and carbapenems. Efforts to develop metallo-β-lactamase (MBL) inhibitors require suitable screening platforms to allow the rapid determination of β-lactamase activity and efficient inhibition. Unfortunately, the platforms currently available are not ideal for this purpose. Further progress in MBL inhibitor identification requires inexpensive and widely applicable assays. Herein the identification of an inexpensive and stable chromogenic substrate suitable for use in assays of clinically relevant MBLs is described. (6R,7R)-3-((4-Nitrophenoxy)methyl)-8-oxo-7-(2-phenylacetamido) -5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 5,5-dioxide (CLS405) was synthesised in a three-step protocol. CLS405 was then characterised spectroscopically, and its stability and kinetic properties evaluated. With a Δλmax value of 100 nm between the parent and hydrolysis product, a higher analytical accuracy is possible with CLS405 than with commonly used chromogenic substrates. The use of CLS405 in assays was validated by MBL activity measurements and inhibitor screening that resulted in the identification of N-hydroxythiazoles as new inhibitor scaffolds for MBLs. Further evaluation of the identified N-hydroxythiazoles against a panel of clinically relevant MBLs showed that they possess inhibitory activities in the mid- to low-micromolar range. The findings of this study provide both a useful tool compound for further inhibitor identification, and novel scaffolds for the design of improved MBL inhibitors with potential as antibiotics against resistant strains of bacteria. Monitoring MBLs! Resistance to β-lactam antibiotics, mediated by metallo-β-lactamases (MBLs), is an increasing clinical problem. While compounds that target MBLs could be useful antibacterial agents, their identification is hampered by the lack of suitable assay platforms. To this end, CLS405, a chromophore-linked MBL substrate, was developed and its applicability demonstrated by the identification of N-hydroxythiazoles as potential inhibitors against a panel of clinically relevant MBLs. Copyright

Hapten synthesis and development of polyclonal antibody-based multi-sulfonamide immunoassays

This paper reports the synthesis of five sulfonamide derivatives, the production of broad-specificity polyclonal antibodies for immunoassay of sulfonamides, and the analysis of milk samples by developed assay. The three-step synthesis procedure reported in most of the literature was adopted and modified in this study. In the procedure, the purification of the intermediate was avoided and the time of synthesis was shortened from >20 to 6-9 h with improved yields. This method is generally applicable to the synthesis of haptens containing the common structure of sulfonamides. Three haptens were coupled to keyhole limpet hemocyanin, and polyclonal antibodies were obtained from rabbits immunized with these conjugates. Using the antibodies obtained, from one of these was developed an enzyme-linked immunosorbent assay (ELISA) based on the competition between free sulfonamides and the hapten-horseradish peroxidase (HRP) conjugates. The hapten-HRP conjugate giving the best competitive results and 11 structurally different sulfonamides showed 50% inhibition at concentrations of -1. After removal of the protein with acetone, milk samples were analyzed by ELISA directly; a matrix effect could be avoided when a 1:20 dilution with phosphate-buffered saline was used, and 104-131% recoveries of spiked samples were obtained. The developed immunoassay is suitable to determine sulfisozole, sulfathiazole, sulfameter, sulfamethoxypyridazine, sulfapyridine, and sulfamethizole below the maximum residue limit in milk (100 ng mL-1 of total sulfonamides) rapidly and reliably.